Zydus FDA Monday, February 29, 2016 +0.40 Positive

FDA Approves GLYBURIDE AND METFORMIN HYDROCHLORIDE — Zydus Pharmaceuticals (USA) Inc.

Zydus Pharmaceuticals (USA) Inc. has received approval for its Abbreviated New Drug Application to market Glyburide and Metformin Hydrochloride, introducing a cost-effective alternative to on-patent branded therapy in the diabetes sector. This approval positions the generic to capture significant market share, providing immediate relief to payers and Medicare Part D programs by lowering the overall cost of glycemic management agents.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed